NETARSUDIL MESYLATE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for netarsudil mesylate and what is the scope of patent protection?
Netarsudil mesylate
is the generic ingredient in one branded drug marketed by Alcon Labs Inc and is included in one NDA. There are fourteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.Netarsudil mesylate has sixty-seven patent family members in fourteen countries.
One supplier is listed for this compound.
Summary for NETARSUDIL MESYLATE
International Patents: | 67 |
US Patents: | 14 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 32 |
Patent Applications: | 39 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for NETARSUDIL MESYLATE |
DailyMed Link: | NETARSUDIL MESYLATE at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for NETARSUDIL MESYLATE
Generic Entry Date for NETARSUDIL MESYLATE*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION/DROPS;OPHTHALMIC |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NETARSUDIL MESYLATE
Drug Class | Rho Kinase Inhibitor |
Mechanism of Action | Rho Kinase Inhibitors |
Paragraph IV (Patent) Challenges for NETARSUDIL MESYLATE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
RHOPRESSA | Ophthalmic Solution | netarsudil mesylate | 0.02% | 208254 | 2 | 2021-12-20 |
US Patents and Regulatory Information for NETARSUDIL MESYLATE
International Patents for NETARSUDIL MESYLATE
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
World Intellectual Property Organization (WIPO) | 2014144781 | ⤷ Try a Trial | |
Japan | 2012525442 | ⤷ Try a Trial | |
Spain | 2852377 | ⤷ Try a Trial | |
Spain | 2834451 | ⤷ Try a Trial | |
Portugal | 3811943 | ⤷ Try a Trial | |
Japan | 2014208681 | ベータおよびガンマ−アミノ−イソキノリンアミド化合物および置換ベンズアミド化合物 (BETA- AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUND AND SUBSTITUTED BENZAMIDE COMPOUND) | ⤷ Try a Trial |
Hong Kong | 1258617 | 雙重機制抑制劑用於治療疾病 (DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for NETARSUDIL MESYLATE
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3053913 | C202030018 | Spain | ⤷ Try a Trial | PRODUCT NAME: NETARSUDIL O UN ENANTIOMERO, DIASTEREOMERO, SAL O SOLVATO DEL MISMO.; NATIONAL AUTHORISATION NUMBER: EU/1/19/1400; DATE OF AUTHORISATION: 20191119; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1400; DATE OF FIRST AUTHORISATION IN EEA: 20191119 |
3053913 | 2020C/510 | Belgium | ⤷ Try a Trial | PRODUCT NAME: RHOKIINSA - NETARSUDIL; AUTHORISATION NUMBER AND DATE: EU/1/19/1400 20191121 |
3053913 | 122020000016 | Germany | ⤷ Try a Trial | PRODUCT NAME: NETARSUDIL, ODER EIN ENANTIOMER, DIASTEREOMER, SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/19/1400 20191119 |
3053913 | 2020/016 | Ireland | ⤷ Try a Trial | PRODUCT NAME: NETARSUDIL, OR AN ENANTIOMER, DIASTEREOMER, SALT OR SOLVATE THEREOF; REGISTRATION NO/DATE: EU/1/19/1400 20191121 |
3461484 | 301101 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: LATANOPROST OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN NETARSUDILMESYLAAT; REGISTRATION NO/DATE: EU/1/20/1502 20210108 |
3053913 | 20C1017 | France | ⤷ Try a Trial | PRODUCT NAME: NETARSUDIL, OU ENANTIOMERE, DIASTEREOMERE, SEL OU SOLVATE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/19/1400 20191121 |
3053913 | 132020000000043 | Italy | ⤷ Try a Trial | PRODUCT NAME: NETARSUDIL(RHOKIINSA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1400, 20191121 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.